You will find 128 million contact lens users worldwide in a 7.5 billion dollar industry and most of them have trouble inserting and/ or removing contact lenses. The result can be as mild as red and irritating eyes and the need to use glasses for a couple of days, but also worst case scenario having to surgically remove the eye. We have designed and created a patented product for inserting and removing contact lenses with a container for keeping the product clean and sterile so you can take it with you.

Unasy AS er en skandinavisk nettbutikk i vekst. Vi har hovedfokus på salg av kvalitetsprodukter innenfor mobiltilbehør og accessories, alltid til lave og konkurransedyktige priser. For å nå målet om å bli markedsledende i Norge og Skandinavia, har vi behov for å utvide vårt team. Unasy er en norsk bedrift som driver med forretningsutvikling.

Better choice - Better lifeVivamart is bringing new exotic products to all its market segment and improving lives using its unique logistics solutions. Buy a bigger variety of products at www.vivamart.no and save time while ordering as well as recieving all products at home. By saving multiple long distance shopping trips, we help to reduce CO2 emissions.

Investant specializes in the development of software solutions related to algorithmic trading. ​We offer 2 services: IT Consultancy: We can develop bespoke trading solutions suited to your specific needs Software Infrastructure: Leverage our in-house developed infrastructure Trading is hard and requires top-notch technology and brains. As we put years into developing self-learning algorithms we leverage every piece of information we can get our hands on and improve day by day. Our technological head-start is and will be a crucial factor in this strongly growing market.

Grasp Your Future Our goal is to increase effectiveness and efficiency of medical treatments through person-centered care and improved clinician-patient communication. Grasp concept One-minute video presenting how Grasp works. Grasp Tracker A patented, CE-marked, and approved medical device. You simply squeeze the device when tracking your symptoms, behavior, and events. Grasp User app Through the user app, the doctor is connected to the patient´s everyday life in real-time: at home, at work, or while engaging in activities. Grasp Clinical solution The doctor can remotely and easily adjust the treatment, modify medical plans or give tailored behavioral feedback to increase the function of the patient

Gain visibility and control over your compliance processes with ease! Our integrated GDPR solution includes consent management, data discovery, documentation, audit logs, assessments, people and customer profiles, and much more. We give you a practical approach to GDPR and "Privacy by design". Get also an award-winning access portal that supports secure Single Sign-On access of data and easy setup of security policies. Mesier, The holistic approach to Cloud governance! Currently, we are 10 highly motivated people with extensive experience in making successful software. Let's talk!

NOFO is founded by passionate food lovers and environmentalists with the goal to inspire plant-based eating with a near-zero carbon footprint. We source all organic ingredients from small local farms to support sustainable farming. By only using high-quality ingredients seasonally harvested by local farmers, we are able to give our customers the best that nature has to offer. How we eat is the most important environmental question facing today's society. Living a plant-based lifestyle will significantly lower your carbon footprint by up to 73%. We want you to join the movement and feel inspired

At Aivero we strive to bring AI to industrial robotics. We are a young and dynamic startup with offices in Norway and Denmark Aivero is a Scandinavian startup founded in 2017 with a mission to democratize automation by simplifying robotic control to the point where anyone can deploy and operate them. No more code, programming, or complex path planning—vision-guided robotics automates this too.

Bemanning er en viktig del av en butikksjefs ansvarsområde. For få ansatte på jobb i forhold til behov vil man miste potensielle salgsmuligheter, og overbemanning vil resultere i at lønnskostnader spiser opp dagens inntjening. Selv om viktigheten av korrekt bemanning er åpenbar, blir det meste av planlegging ofte gjennomført på et mangelfullt datagrunnlag, og i enkelte tilfeller basert på magefølelse. Kunder stiller stadig strengere krav til tilgjengelighet og service, noe som vil føre til at dagens begrensede form for butikkdrift vil tape kampen mot smarte, digitaliserte løsninger

HTTECH's mission is to support heavy industries on the way to sustainable development. HTTECH's vision: Contribute to solving environmental challenges for the established industry in a cost-efficient manner and produce nano-based materials for the future to transform waste into high-value products with high-demand. Build sustainable business in the space of circular economyHTTECH is a company with a solid competence in the field of high-temperature technologiesExpertise: R&D projects in the fields of Hydrogen and Solar Energetics, Energy Savings, Oil&Gas Industry, Computer ModelingMetallurgy & Chemical Engineering, Materials Science and International Business Development Industrial expertise

Oncoinvent AS is a privately held Norwegian company established in 2010. The company is committed to developing new innovative products to provide better treatment options to cancer patients. The innovations being developed by Oncoinvent AS are a result of the extensive experience with the development of radionuclide-based cancer treatments of two of the founders, Dr. Roy H. Larsen and Professor of clinical oncology Øyvind S. Bruland. Larsen and Bruland are the inventors of the first FDA and EMA-approved alpha-emitting pharmaceutical product Xofigo® (Bayer AG), as well as of the beta-emitting radio-immunotherapeutic product candidate Betalutin® (Nordic Nanovector ASA). Oncoinvent's lead product candidate, Radspherin®, is a novel alpha-emitting radioactive microsphere designed for the treatment of metastatic cancers in body cavities. Radspherin® has been shown to cause a significant reduction in tumor cell growth. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be the treatment of peritoneal carcinomatosis. Clinical development will be conducted in collaboration with European and American clinical research centers.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

BusinessClass.com is a sophisticated travel tech startup. Our vision is to become the global leader in premium travel by offering the best travel search, the best travel offers, as well as world-class reviews and other inspirational content. BusinessClass.com is targeting the more quality-minded travellers who want the best travel products at the best possible prices. BusinessClass.com is suitable for both corporate & leisure travel, offering top-quality airline tickets and accommodation. The team and advisers at BusinessClass.com have extensive travel tech industry knowledge. Founder Jason Eckhoff was EY Entrepreneur Of The Year in 2013 when his first online travel company had beaten 28.000 growth companies over a 4-year period. BusinessClass.com is (other than the founder/CEO) backed by a former C-level manager of a major airline and a co-founder of a unicorn (a company valued at more than 1 USD billion). We are currently considering raising additional risk capital for further developing BusinessClass.com and creating the world's best search engine for premium travel!

Inspera is the leading European high-stakes digital examination platform and end-to-end solution for governments, awarding bodies, higher education institutions as well as schools. On a mission to re-invent educational assessment for the 21st century, we offer the most innovative, reliable and secure service as well as the expertise needed digitise large-scale examinations.

Good For Me AS er et ambisiøst selskap som ble etablert i 2013 og har siden oppstart vært en pionér i bransjen. Vår visjon er å være en ledende aktør innen kosttilskudd av høy kvalitet, samt dele kunnskap og inspirasjon som bidrar til å gi folk et bedre og sunnere liv, samtidig som vi tar vare på planeten vår. Alle produktene våre er 100% veganske og det er et verdivalg fra vår side: vi ønsker ikke at produktene våre skal inneholde ingredienser derivert fra dyr eller som er testet på dyr. Produktene selges i vår egen nettbutikk og gjennom over 1000 forhandlere i Norge, primært Vitus Apotek, Ditt Apotek og Apotek 1. Innovasjon er viktig for oss og vi jobber kontinuerlig med produkt- og konseptutvikling, nye markedsføringsmetoder og ny teknologi. Etter å ha inntatt en sterk posisjon oss i det norske markedet, satser vi nå også i Europa.